Search companies

Live

TETRATHERIX LIMITED (ASX: TTX)

Health care · News and insights

Price unavailable

Latest TTX announcements

Announcement Insights

Tetratherix Enters FY27 With First Revenue And A Broader Commercialisation Push

Tetratherix says FY27 is focused on expanding commercial activity, including FDA clearance efforts and initial sales of bone-regeneration products, after becoming revenue-generating in FY26 through its first commercial STEPP supply. It ended FY26 with $34 million in cash, while a separate October quarter update reported approximately $26 million at quarter-end following an $8 million cash reduction, largely for manufacturing investment and research and development. Recent preclinical tendon-repair results also extend the potential use of TegenEOS beyond bone grafting, while the TetraDerm scar trial is complete but remains blinded.

Updated 12 Nov 2026, 08:47 AM Sydney time
Share
SourcesCEO Address to ShareholdersSTRONGER ECONOMICS, LOCAL ECOSYSTEM EXPANSIONApplication for quotation of securities - TTXQuarterly Activities/Appendix 4C Cash Flow ReportDetails of Auditor Appointment/ResignationTegenEOS Biologic Pathway
Comments

Tetratherix Targets First Regenerative Product Sales and Pivotal Trial in FY27

2026-11-12 · Health care

TTX: $6.40 +0.79% · MC: $340M

At its AGM, Tetratherix outlined FY27 plans to pursue US clearance for its bone regeneration products, followed by market seeding and first regenerative product sales. It also plans to enrol the first patients in Tutelix’s pivotal trial and is selecting a long-term partner for TegenEOS. The company said its manufacturing campus would lift capacity tenfold and that MDSAP certification was now in place, after reporting last month that certification was expected in the coming months.

Updated 2026-11-12 13:31
Share
SourcesCEO Address to Shareholders
Comments

Tetratherix Replaces Tiered University Royalties With Flat Revenue Share

2026-11-09 · Health care

TTX: $5.80 +0.00% · MC: $340M

Tetratherix has agreed to pay the University of Sydney a flat royalty of approximately 3% of net product revenue until 2036, replacing tiered royalties, a licence-fee royalty and an indexed minimum royalty. The company says the change is intended to reduce royalties on licensing revenue, simplify administration and provide greater certainty over margins as its products reach market.

Updated 2026-11-09 09:26
Share
SourcesSTRONGER ECONOMICS, LOCAL ECOSYSTEM EXPANSION
Comments

Tetratherix Reports First Product Revenue as FDA Seeks Further Tegenix Details

2026-10-30 · Health care

TTX: $5.50 +2.80% · MC: $340M

Tetratherix generated its first product revenue after shipping STEPP polymer to US partner Superpower Health, ahead of a planned launch next year. The FDA confirmed core elements of the Tegenix submission but requested further chemical characterisation and labelling details. The company ended the quarter with approximately $26 million in cash after an $8 million decrease, and said TetraDerm trial treatment was complete with results still blinded. Following Nexia’s resignation, BDO was appointed auditor, subject to shareholder approval at the upcoming AGM.

Updated 2026-10-30 15:24
Share
SourcesQuarterly Activities/Appendix 4C Cash Flow ReportDetails of Auditor Appointment/Resignation
Comments

Tetratherix Reports Positive Tendon-Repair Results for TegenEOS and PRP

2026-10-29 · Health care

TTX: $5.35 -2.73% · MC: $340M

Tetratherix says its ten-week preclinical study found better tendon healing with TegenEOS carrying platelet-rich plasma (PRP) than with PRP alone, including more organised blood vessels and less inflammation and scar-like tissue at six weeks. The results extend the potential use of TegenEOS, currently a bone-graft carrier, to delivering biologics for soft-tissue repair; the company says the approach is intended to keep PRP at the injury site as it sets into a gel at body temperature.

Updated 2026-10-29 10:18
Share
SourcesTegenEOS Biologic Pathway
Comments